CTOs on the Move

resTORbio

www.restorbio.com

 
resTORbio, Inc. is a clinical stage company, developing medicines to treat aging-related diseases and conditions. resTORbio`s lead program targets the mechanistic target of rapamycin complex 1 (mTORC1) pathway to treat aging-related diseases and conditions. Initially, resTORbio is focused on developing medicines that address conditions caused by immunosenescence, the decline in immune function due to aging. resTORbio has initiated a Phase 2b trial for its lead product candidate, RTB101, evaluating its potential to reduce the incidence of respiratory tract infections (RTI) in elderly individuals at increased risk of RTI-related morbidity and mortality. resTORbio`s lead program is built upon two Phase ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.restorbio.com
  • 501 Boylston Street Suite 6102
    Boston, MA USA 02116
  • Phone: 617.482.2333

Executives

Name Title Contact Details

Funding

resTORbio raised $40M on 11/30/2017

Similar Companies

Inipharm

At Inipharm, we`re building on novel insights and applying our chemistry expertise to develop therapies for patients with liver disease. Inipharm`s lead program is focused on small-molecules to target the activity of HSD17B13, a highly validated, genetically defined target for multiple severe liver and related diseases.

National Institutes of Health

The National Institutes of Health (NIH) is the largest biomedical research agency in the world, conducting research in its own laboratories, supporting the research of non-Federal scientists in universities, medical schools, hospitals, and research ins...

Diosynth

Diosynth is a Des Plaines, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Glen Research Corporation

Glen Research Corporation is a Sterling, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Encorium Group

Encorium Group, Inc is a Berwyn, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.